Back to Journals » Journal of Blood Medicine » Volume 11

Successful Cerebral Hemorrhage Control with Prothrombin Complex Concentrate in a Patient on Edoxaban Therapy: A Case Report

Authors Galbiati G

Received 7 June 2019

Accepted for publication 6 November 2019

Published 30 January 2020 Volume 2020:11 Pages 35—38

DOI https://doi.org/10.2147/JBM.S218636

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Martin H Bluth


Giuseppe Galbiati

Emergency Department, Policlinico San Marco, Zingonia, BG, Italy

Correspondence: Giuseppe Galbiati
Emergency Department
Policlinico San Marco, Zingonia, BG, Italy
Tel +39 035886445
Email galbiati.g@libero.it

Abstract: Direct oral anticoagulants (DOACs) have demonstrated safety and efficacy in stroke prevention in patients with non-valvular atrial fibrillation (NVAF). In terms of safety, there was a significant reduction of intracranial hemorrhages (ICH) in patients treated with DOACs over warfarin. To date, a specific antidote for edoxaban is not yet available. The management of ICH relies on the use of coagulation factors. This article reports a case of a 73-year-old woman with NVAF who had cerebral hematoma in the right intraparenchymal thalamus-capsular area while on therapy with edoxaban 60 mg/day. The computed tomography (CT) brain scan showed hematoma of > 18mm diameter. The patient was timely treated with four-factor prothrombin complex concentrate (4F-PCC) at 50 IU/kg. After 6 hrs patient’s symptoms alleviated and she was successfully recovered within 6 days. A repeated CT scan of the brain in 3 weeks showed improvement. The patient’s treatment with edoxaban 30 mg/day restarted after 8 weeks.

Keywords: non-valvular atrial fibrillation, edoxaban, prothrombin complex concentrate, cerebral hemorrhage

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]